2003 Molecular Therapeutics of Cancer Gordon Conference

描述(由申请者提供)：戈登癌症分子治疗会议致力于将在分子和细胞层面工作的研究科学家与专注于模型生物、实验疗法的临床前评估和临床研究的科学家聚集在一起。与会者代表着广泛的利益，涉及制药行业、生物技术公司以及临床和学术机构。会议旨在通过介绍新的、未发表的工作来促进人类癌症治疗的进步，并集中讨论如何将这些进步应用于患者护理服务。戈登研究会议的非正式性质，以及对高水平科学的高度重视，提供了发人深省和富有洞察力的评论，确保了一次高度互动的会议，激发了关于药物设计和新疗法开发的讨论和新观点。这项申请寻求资金以部分支持2003年会议，该会议将强调在化学药物和新型药物靶标的设计和开发方面的技术进步。蛋白质组学和功能基因组学在药物作用的诊断和机制研究、基于结构的药物设计、识别新的药物靶点和耐药机制的模型系统以及信号抑制物和染色质调节剂的临床开发方面的新机会将突出未来的发展方向。

DESCRIPTION (provided by applicant): The Molecular Therapeutics of Cancer Gordon Conference strives to bring research scientists working at the molecular and cellular level together with scientists whose efforts are focused on model organisms, preclinical evaluation of experimental therapeutics and clinical research. Meeting participants represents a diverse range of interests, spanning the pharmaceutical industry, biotechnology companies, and clinical and academic institutions. The meeting seeks to promote advancements in the treatment of human cancer through the presentation of novel, unpublished work, and to focus on the ways these advancements can be brought to the service of patient care. The informal nature of Gordon Research Conferences and the strong emphasis placed on high-caliber science presented with though-provoking and insightful commentary ensures a highly interactive meeting that stimulates discussion and new perspectives on drug design and development of novel therapeutics. This application seeks funds to partially support the year 2003 conference, which will emphasize technological advances in the design and development of chemothera-peutic agents and novel drug targets. Emerging opportunities in the use of proteomics and functional genomics for diagnosis and mechanistic studies of drug action, structure-based drug design, model system of identifying new drug targets and mechanisms of drug resistance, and the clinical development of signaling inhibitors and chromatin modulators will highlight future directions for progress.